48
Participants
Start Date
September 30, 2011
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Lurasidone
Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Village Clinical Research Inc., New York
Behavioral Medical Research of Staten Island, Staten Island
Finger Lakes Clinical Research, Rochester
CRI Worldwide - Kirkbride, Philadelphia
Psychiatry and Behavioral Sciences, Duke, Durham
Florida Clinical Research Center, LLC, Sarasota
Birmingham Psychiatry Pharmaceutical Studies, Inc, Birmingham
Midwest Clinical Research Center, Dayton
St. Charles Psychiatric Associates/Midwest Research Group, Saint Charles
FutureSearch Trials of Dallas, LP, Dallas
Grayline Clinical Drug Trials, Wichita Falls
Synergy Clinical Research Center, Escondido
Artemis Institute for Clinical Research, San Diego
Collaborative Neuro Science Network, Inc., Garden Grove
Stanford -VA Palo Alto Health Care System, Palo Alto
Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders, Boston
Dept. of Psychiatry, UT Southwestern Medical Center, Dallas
Sumitomo Pharma America, Inc.
INDUSTRY